These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15954940)

  • 21. [Treatment with intravenous iron and ferritin level].
    Fernández-Gallego J; Martín MA; Sujan S; Vega E
    Nefrologia; 2010; 30(3):371-2. PubMed ID: 20514109
    [No Abstract]   [Full Text] [Related]  

  • 22. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of androgens in anaemia resistant to erythropoietin and i.v. iron in patients with heart and renal failure.
    Silverberg D; Wexler D; Blum M; Schwartz D; Iaina A
    Nephrol Dial Transplant; 2004 Apr; 19(4):1021. PubMed ID: 15031380
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
    Conner TA; McQuade C; Olp J; Pai AB
    Biometals; 2012 Oct; 25(5):961-9. PubMed ID: 22706571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C.
    Eiselt J; Racek J; Opatrný K; Trefil L; Stehlík P
    Blood Purif; 2006; 24(5-6):531-7. PubMed ID: 17077626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous iron: the iatrogenic kick to lose control over oxygen?
    Deicher R; Hörl WH
    Kidney Blood Press Res; 2002; 25(5):284-8. PubMed ID: 12435873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
    Silverberg DS; Wexler D; Blum M; Tchebiner J; Sheps D; Keren G; Schwartz D; Baruch R; Yachnin T; Shaked M; Zubkov A; Steinbruch S; Iaina A
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S37-45. PubMed ID: 12227725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic guidelines for renal anemia in Japan].
    Naito M; Akiba T
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():562-5. PubMed ID: 15250369
    [No Abstract]   [Full Text] [Related]  

  • 29. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
    Li H; Wang SX
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy.
    Adhikary L; Acharya S
    JNMA J Nepal Med Assoc; 2011; 51(183):133-6. PubMed ID: 22922860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.
    Kapoian T
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved response to erythropoietin therapy with long-term continuous iron supplementation.
    Descombes E; Fellay G
    Nephron; 2000 Feb; 84(2):196-7. PubMed ID: 10657727
    [No Abstract]   [Full Text] [Related]  

  • 33. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 34. Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin.
    Anbu AT; Kemp T; O'donnell K; Smith PA; Bradbury MG
    Acta Paediatr; 2005 Dec; 94(12):1738-41. PubMed ID: 16431410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introduction to "A road map for intravenous iron and anemia management: preparing for the future".
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S1-4. PubMed ID: 19010256
    [No Abstract]   [Full Text] [Related]  

  • 36. Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.
    Barbieri C; Bolzoni E; Mari F; Cattinelli I; Bellocchio F; Martin JD; Amato C; Stopper A; Gatti E; Macdougall IC; Stuard S; Canaud B
    PLoS One; 2016; 11(3):e0148938. PubMed ID: 26939055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients.
    Nyvad O; Danielsen H; Madsen S
    Lancet; 1994 Nov; 344(8932):1305-6. PubMed ID: 7968018
    [No Abstract]   [Full Text] [Related]  

  • 38. The efficacy of ascorbic acid in suboptimal responsive anemic hemodialysis patients receiving erythropoietin: a meta-analysis.
    Einerson B; Chaiyakunapruk N; Kitiyakara C; Maphanta S; Thamlikitkul V
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S134-46. PubMed ID: 21721439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zinc deficiency anaemia in haemodialysis patients: Often overlooked but a treatable cause of anaemia.
    Taki Y; Imai N; Shibagaki Y
    Nephrology (Carlton); 2017 Dec; 22(12):1037-1038. PubMed ID: 29145703
    [No Abstract]   [Full Text] [Related]  

  • 40. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.